Skip to content

Author

Yi-Qiu Liu

We have 1 of 13 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Oct 2026

Real-world efficacy and safety of neoadjuvant immunochemotherapy in patients with triple-negative breast cancer.

Compared with NAC alone, NAIC significantly improves the pCR rate and reduces the recurrence risk in TNBC patients, with generally manageable toxicity in this real-world cohort, which supports its favorable clinical application value.

Ruo-Xi Xu, Pin-Chao Fan, Yi-Qiu Liu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.